Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab and TACE for Resectable HCC with Vein Thrombosis
NCT04653389Phase 2Terminated
- Sponsor
- Zhejiang University
- Start
- Dec 2020
- Primary completion
- Oct 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of sintilimab in hepatocellular carcinoma (HCC), sponsored by Zhejiang University. Started Dec 2020; status: terminated.
02
Drugs
sintilimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04653389.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04653389.